10975 N. Torrey Pines Road
About Avidity Biosciences
65 articles with Avidity Biosciences
Avidity eligible to receive up to approximately $405 million per target in development and commercialization milestones, plus royalties
The two companies will combine their expertise to drive new immunology candidates toward the clinic.
Avidity Biosciences' Arthur A. Levin Publishes Review of Therapeutic Approaches of Targeting RNA in the New England Journal of Medicine
Arthur A. Levin, Ph.D, executive vice president of research and development at Avidity Biosciences LLC, a biotechnology company advancing Antibody- Oligonucleotide Conjugates (AOCs) as a new class of precision medicines, today published a review titled, "Treating Disease at the RNA Level with Oligonucleotides" in the January 3, 2018, issue of the New England Journal of Medicine1.
Investment advances pre-clinical development of novel exon skipping therapies for treatment of patients with Duchenne muscular dystrophy
Avidity Biosciences Raises $16 Million In Series B Financing To Advance Antibody-Sirna Conjugate Platform